Vtesse, Inc. was established to develop a treatment for patients with Niemann-Pick Type C1 Disease (NPC).
Vtesse, Inc. was Cydan’s first spin co and was dedicated to developing drugs for patients suffering from diseases that are underserved. Vtesse worked collaboratively with the National Institutes of Health (NIH)/National Center for Advancing Translational Sciences (NCATS) and other leading academic centers to advance clinical study of VTS-270 for Niemann-Pick Type C1 Disease (NPC), and to identify and develop other novel drugs for other lysosomal storage diseases (LSDs).
Sucampo Acquires Vtesse, Inc.
In April 2017, Sucampo Pharmaceuticals announced the acquisition of Vtesse for upfront consideration of $200 million ($170 million in cash and $30 million in stock), and a substantial participation in the future success of VTS-270 through an increasing royalty rate. In addition, Cydan shareholders will participate in the value derived from the Pediatric Review Voucher (PRV) to be issued upon approval of the drug.
Mallinckrodt Aquires Sucampo
In December of 2017, Mallinckrodt announced it would acquire Sucampo Pharmaceuticals for approximately $1.2 billion.
For more information, visit http://blog.mallinckrodt.com/our-commitment-to-the-niemann-pick-disease-community/
About Niemann-Pick C (NPC)
NPC is a progressive, irreversible, chronically debilitating – and ultimately lethal – genetic disease. It is caused by a defect in cholesterol transportation within the cell, which leads to excessive and lethal accumulation of cholesterol in the brain. Researchers at the NIH’s National Center for Advancing Translational Sciences (NCATS) and Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), in close collaboration with Vtesse, patients and patient advocacy groups, developed VTS-270 as part of a project focused on finding treatments for NPC. VTS-270 has been shown to significant slow disease progression in animal studies and preliminary indications of efficacy in the Phase I study clinical trial.